On Target to Outsmart Cancer August 2025 © 2025 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and establi ...

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [2] - The company is participating in two upcoming investor conferences, indicating active engagement with the investment community [1][3] Company Overview - Revolution Medicines specializes in RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [2] - The current R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), all of which are in clinical development [2] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [2] - Additional pipeline opportunities include RMC-0708 (Q61H) and RMC-8839 (G13C), focusing on RAS(ON) mutant-selective inhibitors [2] Upcoming Events - The company will participate in the Needham 24 Annual Virtual Healthcare Conference on April 7 at 2:15 p.m. ET [3] - Additionally, Revolution Medicines will be part of the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 1:00 p.m. ET [3]